220 related articles for article (PubMed ID: 15482167)
41. Antiviral therapy of HBV- and HCV-induced liver cirrhosis.
Zavaglia C; Airoldi A; Pinzello G
J Clin Gastroenterol; 2000 Apr; 30(3):234-41. PubMed ID: 10777179
[TBL] [Abstract][Full Text] [Related]
42. Effect of thymosin-α(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B.
Jiang YF; Ma ZH; Zhao PW; Pan Y; Liu YY; Feng JY; Niu JQ
J Int Med Res; 2010; 38(6):2053-62. PubMed ID: 21227010
[TBL] [Abstract][Full Text] [Related]
43. Emergence of an S gene mutant during thymosin alpha1 therapy in a patient with chronic hepatitis B.
Tang JH; Yeh CT; Chen TC; Hsieh SY; Chu CM; Liaw YF
J Infect Dis; 1998 Sep; 178(3):866-9. PubMed ID: 9728561
[TBL] [Abstract][Full Text] [Related]
44. Hepatitis treatment update: new approvals, not much news.
Learned J
Notes Undergr; 1998-1999 Winter; (No 38):7-8. PubMed ID: 11366197
[TBL] [Abstract][Full Text] [Related]
45. Construction, expression and characterization of human interferon alpha2b-(G4S)n-thymosin alpha1 fusion proteins in Pichia pastoris.
Yang YF; Yuan HY; Liu NS; Chen XL; Gao BY; Lu H; Li YY
World J Gastroenterol; 2005 May; 11(17):2597-602. PubMed ID: 15849818
[TBL] [Abstract][Full Text] [Related]
46. Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
Camerini R; Ciancio A; DE Rosa A; Rizzetto M
Ann N Y Acad Sci; 2007 Sep; 1112():368-74. PubMed ID: 17600286
[TBL] [Abstract][Full Text] [Related]
47. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application.
Tao N; Xu X; Ying Y; Hu S; Sun Q; Lv G; Gao J
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110771
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C.
Chien RN; Lin CY; Yeh CT; Liaw YF
J Viral Hepat; 2006 Dec; 13(12):845-50. PubMed ID: 17109685
[TBL] [Abstract][Full Text] [Related]
49. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
Jia Z; Feng Z; Tian R; Wang Q; Wang L
Immunopharmacol Immunotoxicol; 2015; 37(4):388-92. PubMed ID: 26250523
[TBL] [Abstract][Full Text] [Related]
50. Thymosin alpha 1: biological activities, applications and genetic engineering production.
Li J; Liu CH; Wang FS
Peptides; 2010 Nov; 31(11):2151-8. PubMed ID: 20699109
[TBL] [Abstract][Full Text] [Related]
51. [Effects of lamivudine and thymosin alpha1 combination therapy on patients with chronic hepatitis B].
Wu F; Yu H; Huang S
Zhonghua Gan Zang Bing Za Zhi; 2002 Jun; 10(3):218-9. PubMed ID: 12113684
[No Abstract] [Full Text] [Related]
52. Thymosin-alpha 1, but not interferon-alpha, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells.
Moshier JA; Mutchnick MG; Dosescu J; Holtz TK; Akkary S; Mahakala K; Merline JR; Naylor PH
J Hepatol; 1996 Dec; 25(6):814-20. PubMed ID: 9007707
[TBL] [Abstract][Full Text] [Related]
53. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
Zhu S; Zhang H; Dong Y; Wang L; Xu Z; Liu W; Gan Y; Tang H; Chen D; Wang F; Zhao P
J Hepatol; 2018 Jun; 68(6):1123-1128. PubMed ID: 29452204
[TBL] [Abstract][Full Text] [Related]
54. [Clinical trial of sequential antiviral therapy for patients with chronic hepatitis B in China].
Lei CL; Peng XM; Tang XP; Yang Z; Fan HM; Yuan XZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Mar; 18(1):69-72. PubMed ID: 15340532
[TBL] [Abstract][Full Text] [Related]
55. Thymalfasin: an immune system enhancer for the treatment of liver disease.
Sjogren MH
J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S69-72. PubMed ID: 15546253
[TBL] [Abstract][Full Text] [Related]
56. Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C.
Grandini E; Cannoletta F; Scuteri A; Fortini C; Loggi E; Cursaro C; Riili A; Di Donato R; Gramenzi A; Bernardi M; Andreone P
Ann N Y Acad Sci; 2010 Apr; 1194():147-52. PubMed ID: 20536463
[TBL] [Abstract][Full Text] [Related]
57. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.
Rasi G; DiVirgilio D; Mutchnick MG; Colella F; Sinibaldi-Vallebona P; Pierimarchi P; Valli B; Garaci E
Gut; 1996 Nov; 39(5):679-83. PubMed ID: 9026482
[TBL] [Abstract][Full Text] [Related]
58. Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment.
Rustgi V
J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S76-8. PubMed ID: 15546255
[TBL] [Abstract][Full Text] [Related]
59. Thymalfasin for the treatment of chronic hepatitis C infection.
Rustgi VK
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):885-92. PubMed ID: 16307501
[TBL] [Abstract][Full Text] [Related]
60. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection.
Shuqun C; Mengchao W; Han C; Feng S; Jiahe Y; Wenming C; Zhengfeng Y; Yuxiang Z; Peijun W
Hepatogastroenterology; 2006; 53(68):249-52. PubMed ID: 16608033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
